Ping Mu received his B.S. in Biotechnology from Peking University, Beijing, China. He earned his Ph.D. in Biomedical Sciences (Cancer Biology) from Weill Cornell Medical College, where he worked with Dr. Andrea Ventura. There, he identified a microRNA called miR-19 as a crucial oncogenic driver of Myc-driven B cell lymphoma and prostate cancer. This work provided the key rationale for targeting miR-19 to treat these two cancers.
In 2013, Ping joined the laboratory of Dr. Charles L. Sawyers as a postdoctoral fellow at Memorial Sloan Kettering Cancer Center, New York. There, he identified a novel mechanism of antiandrogen resistance in prostate cancer mediated by increased lineage plasticity, or “identity fraud.” This lineage plasticity is enabled by the activation of SOX2 and can be reversed by SOX2 inhibition, which raises the hope that appropriate clinical intervention of lineage plasticity could prevent or overcome resistance.
During his postdoctoral training, Ping conducted an in vivo library screen based on shRNA that identified several candidate genes that confer resistance to antiandrogen therapy. Elucidating the mechanisms by which these genes confer resistance will help us understand antiandrogen resistance and possibly identify novel biomarkers.
- Peking University (2018), Biotechnology
- Graduate School
- Cornell University Medical Col (2018), Biomedical Sciences
- Antiandrogen resistance
- Novel biomarkers
- Prostate cancer
- SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.
- Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, Shah N, Adams EJ, Abida W, Watson PA, Prandi D, Huang CH, de Stanchina E, Lowe SW, Ellis L, Beltran H, Rubin MA, Goodrich DW, Demichelis F, Sawyers CL Science 2017 01 355 6320 84-88
- Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.
- Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, Goodrich MM, Labbé DP, Gomez EC, Wang J, Long HW, Xu B, Brown M, Loda M, Sawyers CL, Ellis L, Goodrich DW Science 2017 01 355 6320 78-83
- An allelic series of miR-17 ~ 92-mutant mice uncovers functional specialization and cooperation among members of a microRNA polycistron.
- Han YC, Vidigal JA, Mu P, Yao E, Singh I, González AJ, Concepcion CP, Bonetti C, Ogrodowski P, Carver B, Selleri L, Betel D, Leslie C, Ventura A Nat. Genet. 2015 Jul 47 7 766-75
- Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas.
- Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P, de Stanchina E, D'Andrea A, Sander C, Ventura A Genes Dev. 2009 Dec 23 24 2806-11
- Targeting Breast Cancer Metastasis.
- Jin X, Mu P Breast Cancer (Auckl) 2015 9 Suppl 1 23-34
- MicroRNAs in Prostate Cancer: Small RNAs with Big Roles.
- Mu P, Deng S, Fan X J Clin Cell Immunol 2015 315 6
- Intact p53-dependent responses in miR-34-deficient mice.
- Concepcion CP, Han YC, Mu P, Bonetti C, Yao E, D'Andrea A, Vidigal JA, Maughan WP, Ogrodowski P, Ventura A PLoS Genet. 2012 8 7 e1002797
- Widespread regulatory activity of vertebrate microRNA* species.
- Yang JS, Phillips MD, Betel D, Mu P, Ventura A, Siepel AC, Chen KC, Lai EC RNA 2011 Feb 17 2 312-26
Honors & Awards
- Deborah and W.A. Tex Moncrief, Jr. Scholar in Medical Research
- CPRIT First-Time, Tenure-Track Faculty Member
- Memorial Sloan Kettering Postdoctoral Researcher Award
- NIH K99/R00 Pathway to Independence Award
- Prostate Cancer Foundation Young Investigator Award
- DoD PCRP Postdoctoral Training Award